Amarin invokes First and Fifth Amendments in law suit challenging FDA off-label promotion

8 May 2015
medical_legal_law_big

Cardiovascular biopharma specialist Amarin (Nasdaq: AMRN) and four independent physicians have filed a law suit to permit off-label promotion.

The law suit, filed in the District Court for the Southern District of New York, seeks a judicial declaration that Food and Drug Administration regulations limiting off-label promotion are unconstitutional under the First and Fifth Amendments. It relates specifically to Amarin’s proposed promotion of its triglyceride-reducing drug Vascepa (icosapent ethyl).

The physicians in the suit say they have First Amendment rights to receive truthful and non-misleading information from Amarin.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical